Last reviewed · How we verify
protoporphyrin
protoporphyrin is a drug. It is currently in unknown development.
Protoporphyrin works by binding to a specific target, although its exact mechanism of action is currently unknown.
Protoporphyrin is a small molecule modality with unknown target and drug class. Its commercial status is unclear, and it has not been approved by the FDA for any indications. As a result, there is limited information available on its pharmacokinetic properties, such as half-life and bioavailability. Protoporphyrin's mechanism of action and safety considerations are also unknown. Further research is needed to determine its potential therapeutic applications and risks.
At a glance
| Generic name | protoporphyrin |
|---|---|
| Target | Cytoplasmic zinc-finger protein, Zinc finger protein mex-5 |
| Therapeutic area | Other |
| Phase | unknown |
Mechanism of action
Imagine a key that fits into a lock. Protoporphyrin is like that key, but instead of unlocking a door, it binds to a specific molecule in the body. This binding can either activate or inhibit the molecule's function, depending on the specific target and the desired therapeutic effect.
Approved indications
Common side effects
Key clinical trials
- Imaging Techniques to Monitor Photosensitizer and sO2 Levels During Photodynamic Therapy of Actinic Keratoses (PHASE2)
- Clinical Significance of Liquid Biopsy in Brain Tumor Patients: a 5-ALA Guided Approach
- Assessment of Skin Lesions Using a Tissue Oxygen Imager Based on Protoporphyrin IX (PPIX) Fluorescence. This is an Open-label, Non-randomized, Feasibility Study That Includes a One-time Application of an FDA Approved Medication Followed by Local Imaging for Benign Skin Growth and Lesions Clinically
- Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants (PHASE2)
- Effect of Bitopertin on the Liver and on Levels of Protoporphyrin IX in Bile, Blood, Liver, and Stool in Patients With Erythropoietic Protoporphyria/X-linked Protoporphyria and Increased Liver Stiffness and/or Liver Enzymes at Baseline (PHASE1)
- Leica Microsystems Sponsored PMCF Study to Collect and Confirm Clinical Data on the Performance of the GLOW400 Device When Used in Accordance With Its Intended Use
- Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Concentrations in Participants With EPP (PHASE2)
- Portable Measurement of Protoporphyrin IX in the Skin
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- protoporphyrin CI brief — competitive landscape report
- protoporphyrin updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about protoporphyrin
What is protoporphyrin?
How does protoporphyrin work?
What development phase is protoporphyrin in?
What does protoporphyrin target?
Related
- Target: All drugs targeting Cytoplasmic zinc-finger protein, Zinc finger protein mex-5
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing